TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12942707

Group type: EXPERIMENTAL
Intervention: Increased colchicine dose in 26 randomly chosen patients with no attacks in the last year.
Number of subjects: 183

Group type: COMPARATOR
Intervention: Not applicable (baseline A‐SAA levels during attack-free period).
Number of subjects: 183

Group type: COMPARATOR
Intervention: Not applicable (comparison of A‐SAA levels based on genetic mutations).
Number of subjects: 183
Study: 10765123

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1,000 mg/m(2)) followed by 5‐FU (600 mg/m(2)) weekly for 3 weeks of every 4
Number of subjects: 36

Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 36
Study: 9375868

Group type: EXPERIMENTAL
Intervention: Radiographs of the feet at baseline and 12 months
Number of subjects: 284
Study: 1609379

Group type: EXPERIMENTAL
Intervention: Normal sodium intake
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Low sodium intake
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High sodium intake
Number of subjects: 17
Study: 3897559

Group type: EXPERIMENTAL
Intervention: Single dose of praziquantel 40 mg/kg bodyweight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Divided dose of praziquantel 2 X 20 mg/kg given 4‐6 h apart
Number of subjects: 0
Study: 31752647

Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR) + Individual Placement and Support (IPS) (n = 28)
Number of subjects: 57

Group type: COMPARATOR
Intervention: IPS alone (n = 29)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: CR + IPS
Number of subjects: 57
Study: 31176295

Group type: EXPERIMENTAL
Intervention: Real acupuncture treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham acupuncture treatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pre-treatment resting-state functional connectivity (rsFC)
Number of subjects: 50
Study: 29223508

Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol combination via dry powder inhalers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled FOR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled BUD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Potential covariates
Number of subjects: 0
Study: 26847320

Group type: EXPERIMENTAL
Intervention: Robot active assisted therapy (RT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Classical occupational therapy (OT)
Number of subjects: 17
Study: 23754782

Group type: EXPERIMENTAL
Intervention: Intervention group (MOVE/me Muevo)
Number of subjects: 541

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 541
Study: 23722990

Group type: EXPERIMENTAL
Intervention: D-cycloserine-augmented exposure and response prevention (ERP + DCS)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo-augmented exposure and response prevention (ERP + PBO)
Number of subjects: 17
Study: 20668807

Group type: EXPERIMENTAL
Intervention: Postpartum women with PPD
Number of subjects: 440
Study: 17517442

Group type: EXPERIMENTAL
Intervention: Health counseling, guidance, and adjustment education (1 guidance and counseling session + 4 sessions within 12 months)
Number of subjects: 117
Study: 16880426

Group type: EXPERIMENTAL
Intervention: Plant-based diet intervention
Number of subjects: 0
Study: 12880874

Group type: EXPERIMENTAL
Intervention: Print program (8-week, stage-targeted)
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Web program (8-week, stage-targeted)
Number of subjects: 655
Study: 10963640

Group type: EXPERIMENTAL
Intervention: FEC 75 (11 cycles of fluorouracil 500 mg/m(2), epirubicin 75 mg/m(2), and cyclophosphamide 500 mg/m(2) every 21 days)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: FEC 100 (four cycles of epirubicin 100 mg/m(2) then eight cycles of epirubicin 50 mg/m(2))
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: FEC 100 followed by retreatment at disease progression
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: FEC 100 (four cycles)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: FEC 100 (arm B)
Number of subjects: 417

Group type: COMPARATOR
Intervention: FEC 75 (arm A)
Number of subjects: 417

Group type: COMPARATOR
Intervention: FEC 100 followed by retreatment at disease progression (arm C)
Number of subjects: 417
Study: 7534423

Group type: EXPERIMENTAL
Intervention: Raclopride at 12 mg/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Raclopride at 2 mg/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Raclopride at 6 mg/day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Haloperidol at 15 mg/day
Number of subjects: 32
Study: 3362801

Group type: EXPERIMENTAL
Intervention: Motivational videotapes
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum (brief individual treatment)
Number of subjects: 603

Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 603

Group type: COMPARATOR
Intervention: Invited but did not attend (control group)
Number of subjects: 603
Study: 31773749

Group type: EXPERIMENTAL
Intervention: Selective caries removal (SR)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Non-selective removal to hard dentine
Number of subjects: 255
Study: 30414528

Group type: EXPERIMENTAL
Intervention: nal-IRI+5-FU/LV
Number of subjects: 66

Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 66
Study: 28259039

Group type: EXPERIMENTAL
Intervention: Forward step training (FT)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Lateral plus forward step training (FLT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No training (NT)
Number of subjects: 54
Study: 27235824

Group type: EXPERIMENTAL
Intervention: Semantic priming with healthy body image words (e.g., 'slim', 'fit')
Number of subjects: 161

Group type: COMPARATOR
Intervention: Neutral prime
Number of subjects: 161
Study: 23510061

Group type: EXPERIMENTAL
Intervention: Academic detailing (AD)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Direct mail (DM)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 241
Study: 21086245

Group type: EXPERIMENTAL
Intervention: Clown visit
Number of subjects: 100

Group type: COMPARATOR
Intervention: No-visit control
Number of subjects: 100
Study: 20002421

Group type: EXPERIMENTAL
Intervention: Birth education program for expectant fathers
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 87
Study: 17307102

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 4724

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 4724
Study: 15489085

Group type: EXPERIMENTAL
Intervention: Combined therapy (antiplatelet plus moderate-intensity anticoagulation)
Number of subjects: 1209

Group type: COMPARATOR
Intervention: Anticoagulant therapy
Number of subjects: 1209
Study: 11181493

Group type: EXPERIMENTAL
Intervention: Busulfan at a dose of 16 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma alpha GST levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hepatic GST activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma alpha GST concentrations
Number of subjects: 0
Study: 9692701

Group type: EXPERIMENTAL
Intervention: Liquid Gaviscon (20 ml dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tap water (control group)
Number of subjects: 12
Study: 8558412

Group type: EXPERIMENTAL
Intervention: Combined aerobic and weight training (n = 22)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Ordinary aerobic training alone (n = 19)
Number of subjects: 59

Group type: COMPARATOR
Intervention: No physical training (n = 18)
Number of subjects: 59
Study: 2196536

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 10 mg orally
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Acetaminophen 600 mg plus codeine 60 mg orally
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 273321

Group type: EXPERIMENTAL
Intervention: Silka toothpaste
Number of subjects: 0

Group type: COMPARATOR
Intervention: Toothpaste without periodontal‐prophylactic adjuncts
Number of subjects: 0
Study: 30866143

Group type: EXPERIMENTAL
Intervention: Dacryocystography (DCG)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Dacryoscintigraphy (DSG)
Number of subjects: 165
Study: 29229659

Group type: EXPERIMENTAL
Intervention: Mirroring intervention using the Smokerface app for 45 minutes, delivered by medical students.
Number of subjects: 735

Group type: COMPARATOR
Intervention: Control group (not specified intervention).
Number of subjects: 735
Study: 26053411

Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvest (EVH)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Open vein harvest (OVH)
Number of subjects: 126
Study: 23906899

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 43
Study: 21751285

Group type: EXPERIMENTAL
Intervention: Diffusion-weighted imaging (DWI)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Magnetic resonance (MR) volumetry
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Early tumor volume reduction rate
Number of subjects: 34

Group type: COMPARATOR
Intervention: Tumor regression grade (TRG)
Number of subjects: 34
Study: 19537357

Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (Exubera) three times daily prior to meals
Number of subjects: 40

Group type: COMPARATOR
Intervention: Subcutaneous insulin glargine (Lantus) once daily
Number of subjects: 40
Study: 16719028

Group type: EXPERIMENTAL
Intervention: Task-oriented intervention (practice of functional, unilateral and bilateral tasks)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Walking tasks (control intervention)
Number of subjects: 91
Study: 15317830

Group type: EXPERIMENTAL
Intervention: Solifenacin succinate 5 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Solifenacin succinate 10 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Solifenacin succinate 20 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Solifenacin succinate 30 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Solifenacin succinate 100 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Solifenacin succinate (various doses)
Number of subjects: 2
Study: 10945312

Group type: EXPERIMENTAL
Intervention: Moxonidine 0.6 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Moxonidine 0.9 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Moxonidine 1.2 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 9243349

Group type: COMPARATOR
Intervention: 9-cis-retinoic acid (5 mg, 15 mg, 40 mg, 80 mg, 150 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 9-cis-retinoic acid (various doses)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7954483

Group type: EXPERIMENTAL
Intervention: moclobemide (300 mg daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: maprotiline (75 mg daily)
Number of subjects: 80
Study: 3118861

Group type: EXPERIMENTAL
Intervention: Enprostil (35 micrograms capsule)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Ranitidine (150 mg tablet)
Number of subjects: 164
Study: 29669531

Group type: EXPERIMENTAL
Intervention: IIV4-I
Number of subjects: 1981
Study: 25490158

Group type: EXPERIMENTAL
Intervention: Interpersonal Support in Physical Activity Consultations Observational Tool (ISPACOT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Low interpersonally supportive features consultations
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Trained advisors in Self-determination Theory (SDT) principles
Number of subjects: 42
Study: 24238714

Group type: EXPERIMENTAL
Intervention: Buprenorphine treatment
Number of subjects: 297
Study: 22995653

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (1000 mg, once daily) plus prednisone (5 mg, orally twice daily)
Number of subjects: 1195

Group type: COMPARATOR
Intervention: Placebo plus prednisone (5 mg, orally twice daily)
Number of subjects: 1195
Study: 21105368

Group type: EXPERIMENTAL
Intervention: Phototherapy with visible and near infrared light (480‐3400 nm, 95 % polarization, 40 mW/cm2, 12 J/cm2) for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phototherapy with visible and near infrared light
Number of subjects: 0
Study: 18953051

Group type: EXPERIMENTAL
Intervention: BMC conditioned supernatants (BMC-SN)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PBL conditioned supernatants (PBL-SN)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: BMC-SN and PBL-SN in combination
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: BMCs and PBLs
Number of subjects: 15
Study: 15683890

Group type: EXPERIMENTAL
Intervention: Acid etching
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sandblasting prior to acid etching
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lingual bonding
Number of subjects: 50

Group type: COMPARATOR
Intervention: Buccal bonding
Number of subjects: 50
Study: 12841540

Group type: EXPERIMENTAL
Intervention: Oral calcium gluconolactate administration (1 g)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Combined parameters of Product P and Ratio R
Number of subjects: 102
Study: 10391666

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg twice a day for 7 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8853756

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg once daily (L15)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily (L30)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Ranitidine 300 mg b.d. (R600)
Number of subjects: 235
Study: 1737544

Group type: EXPERIMENTAL
Intervention: Glipizide (11.9 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Glyburide (8.4 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both treatments (Glipizide and Glyburide)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 21
Study: 6336862

Group type: EXPERIMENTAL
Intervention: Combination of gentamicin (80 mg) and clindamycin (600 mg) administered intravenously, three doses daily for 2 days.
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Combination of gentamicin (80 mg) and metronidazole (500 mg) administered intravenously, three doses daily for 2 days.
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group receiving a barium enema for radiologic assessment.
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Both interventions (gentamicin with clindamycin and gentamicin with metronidazole).
Number of subjects: 107
Study: 29993436

Group type: EXPERIMENTAL
Intervention: Domain-invariant projection ensemble approach with a 'sampling-and-fusion' framework
Number of subjects: 0
Study: 29893422

Group type: EXPERIMENTAL
Intervention: Standard itraconazole pulse therapy (200 mg twice per day, 1 week each month for three pulses)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Long-term pulse therapy (200 mg twice per day, 1 week each month for six pulses)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low-dose and long-term pulse therapy (200 mg/d, 1 week per month for six pulses)
Number of subjects: 90
Study: 26856901

Group type: EXPERIMENTAL
Intervention: Exposure to 40, 80, or 120 road, rail, and/or air traffic noise events (including one noise-free control night)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Exposure to 80 noise events per night (4 exposure nights)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Exposure to 40, 80, or 120 road, rail, and/or air traffic noise events
Number of subjects: 69

Group type: COMPARATOR
Intervention: Noise-free control night
Number of subjects: 69
Study: 24445389

Group type: EXPERIMENTAL
Intervention: 5 mL 0.5% levobupivacaine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 5 mL 2% lidocaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: 5 mL 0.9% saline (control group)
Number of subjects: 90
Study: 23232203

Group type: EXPERIMENTAL
Intervention: Nasal saline irrigation
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control (no nasal saline irrigation)
Number of subjects: 79
Study: 19436684

Group type: EXPERIMENTAL
Intervention: General physical training (GPT); walking and stair climbing exercises; trained daily for 30 minutes for eight weeks.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Inspiratory muscle training (IMT); targeted breathing through inspiratory resistances; trained daily for 30 minutes for eight weeks.
Number of subjects: 16
Study: 17564015

Group type: EXPERIMENTAL
Intervention: Indapamide retard (1.5 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25 mg/day)
Number of subjects: 50
Study: 14757271

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 40 mg plus estradiol valerate 2 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo plus estradiol valerate 2 mg
Number of subjects: 50
Study: 11848548

Group type: EXPERIMENTAL
Intervention: Sucralfate gel (1 gr.) applied 3 times daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sucralfate gel (1 gr.)
Number of subjects: 40
Study: 10193395

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (NCPAP) at pressures of 0, 5, and 10 cm H2O
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 11
Study: 8163718

Group type: EXPERIMENTAL
Intervention: OPC-18790 (0.05, 0.1, 0.2, or 0.4 mg/kg intravenous dose)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: OPC-18790 (1-hour infusion of 0.5, 1.0, 2.5, 5.0, 10.0, or 15.0 micrograms/kg/minute)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 3283919

Group type: EXPERIMENTAL
Intervention: Famotidine, 40 mg at night
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 28822028

Group type: EXPERIMENTAL
Intervention: Diquafosol tetrasodium 3% (group A)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Sodium hyaluronate 0.1% (group B)
Number of subjects: 94
Study: 27488071

Group type: COMPARATOR
Intervention: Low-dose rAAV.sFlt‐1 (1 × 10 vector genomes)
Number of subjects: 6

Group type: COMPARATOR
Intervention: High-dose rAAV.sFlt‐1 (1 × 10 vector genomes)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 6
Study: 24477462

Group type: EXPERIMENTAL
Intervention: 1 % terbinafine film-forming solution (FFS)
Number of subjects: 290
Study: 22781292

Group type: EXPERIMENTAL
Intervention: Combination of rh‐Endostatin (7.5 mg/m(2), d1‐d14) with neoadjuvant DE regimen (docetaxel: 75 mg/m(2), d1, epirubicin: 75 mg/m(2), d1)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Neoadjuvant DE regimen (docetaxel: 75 mg/m(2), d1, epirubicin: 75 mg/m(2), d1) alone
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Combination of rh‐Endostatin with neoadjuvant DE regimen
Number of subjects: 68

Group type: COMPARATOR
Intervention: Neoadjuvant DE regimen alone
Number of subjects: 68
Study: 20044128

Group type: EXPERIMENTAL
Intervention: Carboplatin plus pegylated liposomal doxorubicin (PLD) (30 mg/m(2))
Number of subjects: 61

Group type: COMPARATOR
Intervention: Single agent carboplatin (AUC 5)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Carboplatin plus PLD (30 mg/m(2))
Number of subjects: 61
Study: 18047753

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches (7 mg/24 h)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 15883442

Group type: EXPERIMENTAL
Intervention: Vitamin therapy (0.5 mg cyanocobalamin, 0.8 mg folic acid, 3 mg vitamin B‐6)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 12823149

Group type: EXPERIMENTAL
Intervention: Beclometasone dipropionate (BDP) 5 mg/day o.d.
Number of subjects: 177

Group type: COMPARATOR
Intervention: 5-ASA 0.8 g t.d.s.
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Beclometasone dipropionate (BDP)
Number of subjects: 177
Study: 11938806

Group type: EXPERIMENTAL
Intervention: Supplementary moxibustion on Shenque (Ren 8) point during radio- and chemotherapy (30 sessions).
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (radio- and chemotherapy without moxibustion).
Number of subjects: 56
Study: 8796367

Group type: EXPERIMENTAL
Intervention: Cyproheptadine 16 mg day-1
Number of subjects: 6
Study: 1299247

Group type: EXPERIMENTAL
Intervention: Scotchbond 2 adhesive and Silux Plus resin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tenure adhesive and Perfection resin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fuji glass ionomer (Control)
Number of subjects: 120
Study: 6591370

Group type: EXPERIMENTAL
Intervention: Straight multitufted toothbrush
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: V-shaped toothbrush
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Straight multitufted toothbrush (professionally used)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: V-shaped toothbrush (professionally used)
Number of subjects: 24
Study: 31543976

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29247433

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 27760089

Group type: EXPERIMENTAL
Intervention: Tribulus terrestris 750 mg/d for 120 days
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 25456571

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy plus prize-based contingency management (CBT + prizeCM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT) alone
Number of subjects: 60
Study: 22333882

Group type: EXPERIMENTAL
Intervention: Genital Teaching Associates (GTA) first session
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pelvic Simulator (SIM) first session
Number of subjects: 100
Study: 20179502

Group type: EXPERIMENTAL
Intervention: Pressure-limiting group (LMA intracuff pressure <44 mmHg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Routine care group (no intervention)
Number of subjects: 200
Study: 17118950

Group type: EXPERIMENTAL
Intervention: SHARE programme
Number of subjects: 4196

Group type: COMPARATOR
Intervention: Existing sex education (control group)
Number of subjects: 4196
Study: 16193589

Group type: EXPERIMENTAL
Intervention: Bupivacaine (5 mg/ml)‐epinephrine (5 microg/ml) infiltration
Number of subjects: 64

Group type: COMPARATOR
Intervention: Saline infiltration (Control)
Number of subjects: 64